Integra LifeSciences Holdings Corporation (IART) VP Sells $70,785.00 in Stock

Integra LifeSciences Holdings Corporation (NASDAQ:IART) VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up $0.08 on Friday, reaching $47.56. The company’s stock had a trading volume of 262,400 shares, compared to its average volume of 609,337. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. The firm has a market cap of $3,730.00, a P/E ratio of 26.18, a PEG ratio of 2.06 and a beta of 0.64. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The company’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 earnings per share. research analysts anticipate that Integra LifeSciences Holdings Corporation will post 1.87 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) VP Sells $70,785.00 in Stock” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://sportsperspectives.com/2017/11/18/integra-lifesciences-holdings-corporation-iart-vp-sells-70785-00-in-stock.html.

A number of institutional investors and hedge funds have recently modified their holdings of IART. Teachers Advisors LLC raised its holdings in Integra LifeSciences Holdings Corporation by 105.7% in the 1st quarter. Teachers Advisors LLC now owns 106,897 shares of the life sciences company’s stock valued at $4,504,000 after acquiring an additional 54,933 shares during the last quarter. Morgan Stanley grew its stake in shares of Integra LifeSciences Holdings Corporation by 243.3% during the 1st quarter. Morgan Stanley now owns 344,498 shares of the life sciences company’s stock valued at $14,513,000 after buying an additional 244,162 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Integra LifeSciences Holdings Corporation during the 1st quarter valued at $7,316,000. Schwab Charles Investment Management Inc. grew its stake in shares of Integra LifeSciences Holdings Corporation by 116.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 244,982 shares of the life sciences company’s stock valued at $10,322,000 after buying an additional 131,995 shares during the period. Finally, State Street Corp grew its stake in shares of Integra LifeSciences Holdings Corporation by 116.5% during the 1st quarter. State Street Corp now owns 1,497,043 shares of the life sciences company’s stock valued at $63,070,000 after buying an additional 805,426 shares during the period. Institutional investors own 83.60% of the company’s stock.

Several research analysts recently issued reports on IART shares. Zacks Investment Research downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Barclays PLC restated an “equal weight” rating and set a $53.00 price objective (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. BidaskClub downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $60.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, September 18th. Finally, Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $53.82.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply